Immunophenotypic stability of Sézary cells by flow cytometry usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy

American Journal of Clinical Pathology

Volumn 137, Issue 3, 2012, Pages 403-411

  Vaughan, James ^a   Harrington, Alexandra M ^a   Hari, Parameswaran N ^a   Kroft, Steven H ^a   Olteanu, Horatiu ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Alemtuzumab; Flow cytometry; Immunophenotype; S zary

Indexed keywords

ALEMTUZUMAB; CD2 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD5 ANTIGEN; CD7 ANTIGEN; DIPEPTIDYL PEPTIDASE IV; INTERFERON; T LYMPHOCYTE RECEPTOR BETA CHAIN; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; MONOCLONAL ANTIBODY; TUMOR MARKER;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CD4 CD8 RATIO; CD4 LYMPHOCYTE PERCENTAGE; CELL CLONE; CELL COUNT; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; MALE; MYCOSIS FUNGOIDES; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUVA; RETROSPECTIVE STUDY; SEZARY CELL; SEZARY SYNDROME; SKIN BIOPSY; SOUTHERN BLOTTING; STEM CELL TRANSPLANTATION; TOTAL SKIN ELECTRON THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; ULTRAVIOLET RADIATION; BLOOD CELL COUNT; DRUG MONITORING; METABOLISM; METHODOLOGY; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS; BLOOD CELL COUNT; DRUG MONITORING; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; MALE; MIDDLE AGED; MYCOSIS FUNGOIDES; SEZARY SYNDROME; TUMOR MARKERS, BIOLOGICAL;

EID: 84859238276     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP7QHH5XASTJPL     Document Type: Article

References (27)

1. Ralfkiaer E, Cerroni L, Sander CA, et al.Mycosis fungoides. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:296-298.
2. Ralfkiaer E, Willemze R, Whittaker SJ. Sézary syndrome. In: Swerdlow SH, Campo E, Harris NL, et al. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:299.
3. Scarisbrick JJ, Whittaker S, Evans AV, et al.Prognostic significance of tumor burden in the blood of patients with erythrodermic primary cutaneous T-cell lymphoma. Blood. 2001;97:624-630. (Pubitemid 32113393)
4. Kim YH, Liu HL, Mraz-Gernhard S, et al.Long-term outcome of 525 patients with mycosis fungoides and Sézary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol. 2003;139:857-866. (Pubitemid 36898920)
5. Olsen E, Vonderheid E, Pimpinelli N, et al.Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110:1713-1722. (Pubitemid 47443880)
6. Meyer CJ, van Leeuwen AW, van der Loo EM, et al.Cerebriform (Sézary like) mononuclear cells in healthy individuals: a morphologically distinct population of T cells: relationship with mycosis fungoides and Sézary's syndrome. Virchows Arch B Cell Pathol. 1977;25:95-104. (Pubitemid 8228172)
7. Lutzner MA, Emerit I, Durepaire R, et al.Cytogenetic, cytophotometric, and ultrastructural study of large cerebriform cells of the Sézary syndrome and description of a small-cell variant. J Natl Cancer Inst. 1973;50:1145-1162.
8. Lutzner MA, Hobbs JW, Horvath P. Ultrastructure of abnormal cells in Sézary syndrome, mycosis fungoides, and parapsoriasis en plaque. Arch Dermatol. 1971;103:375-386.
9. Feng B, Jorgensen JL, Jones D, et al.Flow cytometric detection of peripheral blood involvement by mycosis fungoides and Sézary syndrome using T-cell receptor Vbeta chain antibodies and its application in blood staging. Mod Pathol. 2010;23:284-295.
10. Kelemen K, Guitart J, Kuzel TM, et al.The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol. 2008;129:146-156. (Pubitemid 352038603)
11. β analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome. Am J Clin Pathol. 2006;125:364-374.
12. Bernengo MG, Novelli M, Quaglino P, et al.The relevance of the CD4+ CD26- subset in the identification of circulating Sézary cells. Br J Dermatol. 2001;144:125-135. (Pubitemid 32154603)
13. Borowitz MJ, Weidner A, Olsen EA, et al.Abnormalities of circulating T-cell subpopulations in patients with cutaneous T-cell lymphoma: cutaneous lymphocyte-associated antigen expression on T cells correlates with extent of disease. Leukemia. 1993;7:859-863. (Pubitemid 23210865)
14. Jones D, Dang NH, Duvic M, et al.Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol. 2001;115:885-892. (Pubitemid 32476716)
15. Gorczyca W, Weisberger J, Liu Z, et al.An approach to diagnosis of T-cell lymphoproliferative disorders by flow cytometry. Cytometry. 2002;50:177-190. (Pubitemid 37517317)
16. Vonderheid EC, Bernengo MG, Burg G, et al.Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002;46:95-106. (Pubitemid 34073484)
17. Schwab C, Willers J, Niederer E, et al.The use of anti-T-cell receptor-Vbeta antibodies for the estimation of treatment success and phenotypic characterization of clonal T-cell populations in cutaneous T-cell lymphomas. Br J Haematol. 2002;118:1019-1026. (Pubitemid 35025964)
18. Washington LT, Huh YO, Powers LC, et al.A stable aberrant immunophenotype characterizes nearly all cases of cutaneous T-cell lymphoma in blood and can be used to monitor response to therapy. BMC Clin Pathol. 2002;2:5.doi:.
19. Jamal S, Picker LJ, Aquino DB, et al.Immunophenotypic analysis of peripheral T-cell neoplasms: a multiparameter flow cytometric approach. Am J Clin Pathol. 2001;116:512-526. (Pubitemid 34450285)
20. Lust JA. Molecular genetics and lymphoproliferative disorders. J Clin Lab Anal. 1996;10:359-367. (Pubitemid 26398922)
21. Ortonne N, Huet D, Gaudez C, et al.Significance of circulating T-cell clones in Sézary syndrome. Blood. 2006;107:4030-4038. (Pubitemid 43726811)
22. Harmon CB, Witzig TE, Katzmann JA, et al.Detection of circulating T cells with CD4+CD7- immunophenotype in patients with benign and malignant lymphoproliferative dermatoses. J Am Acad Dermatol. 1996;35(3 pt 1):404-410.
23. β expression in the evaluation of peripheral blood involvement by T-ell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques. Am J Clin Pathol. 2004;121:373-383.
24. Vonderheid EC, Boselli CM, Conroy M, et al.Evidence for restricted Vbeta usage in the leukemic phase of cutaneous T cell lymphoma. J Invest Dermatol. 2005;124:651-661. (Pubitemid 40381590)
25. Kennedy B, Rawstron A, Carter C, et al.Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood. 2002;99:2245-2247. (Pubitemid 34525514)
26. Kennedy GA, Seymour JF, Wolf M, et al.Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol. 2003;71:250-256. (Pubitemid 37174695)
27. Spears MD, Harrington AM, Kroft SH, et al.Immunophenotypic stability of T-cell large granular lymphocytic leukaemia by flow cytometry. Br J Haematol. 2010;151:97-99.